文献速递瓣膜外科

一站式经导管双瓣置换:同期处理主动脉瓣与二尖瓣

Integrated double redo percutaneous valve replacement: simultaneous transcatheter aortic and mitral valve management.
PubMed 文献 · Eur J Cardiothorac Surg · 2025-01-01

该单中心回顾性研究分析了2018年10月至2024年4月接受同期经导管主动脉瓣植入(TAVI)与经导管二尖瓣植入(TMVI)的13例患者,中位年龄77岁,中位EuroSCORE II为16.9%。结果显示100%技术成功、30天死亡率0%、30天器械成功与早期安全/MVARC手术成功均为100%,无重大不良事件,NYHA心功能分级中位数从III级改善至II级。作者认为对于选定患者,经导管双瓣植入(TDVI)是外科再次双瓣置换的安全有效替代方案,但需更大规模前瞻性多中心研究验证长期效果。

要点

  • TDVI在13例高外科风险患者中实现100%技术成功和0%的30天死亡率。
  • 30天器械成功与早期安全/MVARC手术成功均为100%,无重大不良事件。
  • NYHA心功能分级中位数从III级改善至II级,早期疗效良好。

核心结论

  • 对于选定患者,TDVI似乎是外科再次双瓣置换的安全有效替代方案,早期结果优异。

研究设计与样本

  • 单中心回顾性分析纳入2018年10月至2024年4月同期接受TAVI和TMVI的全部13例患者。

主要发现

  • 患者中位年龄77岁,女性7/13(53.8%),中位EuroSCORE II为16.9%。
  • 所有患者均存在结构性瓣膜退化,符合VARC-3定义的严重血流动力学瓣膜恶化。
  • 手术结局显示100%技术成功,30天死亡率为0%。
  • 30天器械成功和早期安全/MVARC手术成功均为100%,无重大不良事件发生。
  • TDVI后NYHA功能分级中位数从III级改善至II级。

关键数值与推荐

  • 主要终点为VARC-3和MVARC技术成功、30天器械成功和早期安全(MVARC手术成功)。

临床怎么用

  • 对于外科再次双瓣置换高风险的选择性患者,可考虑一站式TDVI作为替代方案。

局限性

  • 单中心回顾性设计,样本量仅13例,证据有限。
  • 需要更大规模前瞻性多中心研究验证长期效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The growing elderly population contributes to an increasing prevalence of severe degenerative native aortic valve (AV) or mitral valve (MV) disease in combination with bio-prosthetic valve failure of prior implanted (aortic or mitral) bio-prostheses, as well as concomitant failure of both aortic and mitral bio-prosthetic valves. A combined surgical AV and MV replacement carries a markedly higher risk, especially in the redo setting. Transcatheter double-valve implantation (TDVI) is emerging as a promising alternative that may mitigate the risks of redo surgery. The evidence for TDVI is very limited. This study aims to address the current gap in the literature by analysing a large institutional series of single-stage TDVI. METHODS: Single-centre retrospective analysis of all patients (n = 13) undergoing simultaneous transcatheter aortic valve implantation (TAVI) and transcatheter mitral valve implantation (TMVI) from October 2018 until April 2024. Primary end-points were Valve Academic Research Consortium-3 (VARC-3) and Mitral Valve Academic Research Consortium (MVARC) technical success, 30-day device success and early safety (MVARC procedural success). Secondary end-points included echocardiographic TDVI performance, adverse events, symptom change and survival. RESULTS: The median age of patients was 77 years, with 7/13 (53.8%) females. Median EuroSCORE II was 16.9%. All patients presented with structural valve degeneration with severe haemodynamic valve deterioration according to the VARC-3 definition. Procedural outcomes showed 100% technical success. There was absence of 30-day mortality (0%). Thirty-day device success and early safety/MVARC procedural success were 100%. No major adverse events occurred. After TDVI, the median New York Heart Association functional class improved from III to II. CONCLUSIONS: TDVI appears to be a safe and effective alternative to surgical redo double-valve replacement for selected patients. Our findings support the feasibility of TDVI with excellent early outcomes. Further prospective multicentre studies with larger cohorts are needed to validate the long-term effects and to establish TDVI as a guideline consideration.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Hinkov H, Lee CB, Greve D, et al. Integrated double redo percutaneous valve replacement: simultaneous transcatheter aortic and mitral valve management. Eur J Cardiothorac Surg. 2025. PMID: 39913425. doi:10.1093/ejcts/ezaf023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。